HC Wainwright Reiterates “Buy” Rating for Lumos Pharma (NASDAQ:LUMO)

Lumos Pharma (NASDAQ:LUMO)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $28.00 price target on the stock.

A number of other equities analysts have also recently issued reports on the stock. Oppenheimer reduced their price objective on shares of Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. EF Hutton Acquisition Co. I raised Lumos Pharma to a “strong-buy” rating in a research note on Tuesday, September 24th.

Lumos Pharma Stock Performance

NASDAQ LUMO opened at $3.94 on Friday. The stock has a market capitalization of $31.99 million, a P/E ratio of -0.86 and a beta of 0.78. Lumos Pharma has a 52 week low of $1.37 and a 52 week high of $4.55. The stock has a fifty day moving average of $3.03 and a 200-day moving average of $2.68.

Lumos Pharma (NASDAQ:LUMO) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.33. The firm had revenue of $0.49 million during the quarter. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. During the same period in the prior year, the firm posted ($1.09) earnings per share. Equities research analysts forecast that Lumos Pharma will post -2.56 earnings per share for the current fiscal year.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.